Compare CMCO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCO | LCTX |
|---|---|---|
| Founded | 1875 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.3M | 393.9M |
| IPO Year | 1996 | N/A |
| Metric | CMCO | LCTX |
|---|---|---|
| Price | $17.05 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $35.00 | $4.25 |
| AVG Volume (30 Days) | 258.9K | ★ 2.2M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $977,994,000.00 | $10,816,000.00 |
| Revenue This Year | $5.60 | $5.24 |
| Revenue Next Year | $4.23 | $126.78 |
| P/E Ratio | $129.86 | ★ N/A |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $11.78 | $0.37 |
| 52 Week High | $41.05 | $2.09 |
| Indicator | CMCO | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 50.96 |
| Support Level | $16.16 | $1.57 |
| Resistance Level | $16.56 | $1.76 |
| Average True Range (ATR) | 0.63 | 0.11 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 88.41 | 44.16 |
Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.